首页> 美国卫生研究院文献>Antimicrobial Agents and Chemotherapy >Pharmacokinetics of cefepime in patients undergoing continuous ambulatory peritoneal dialysis.
【2h】

Pharmacokinetics of cefepime in patients undergoing continuous ambulatory peritoneal dialysis.

机译:头孢吡肟在连续非卧床腹膜透析患者体内的药代动力学。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

The pharmacokinetics of cefepime were studied in 10 male patients receiving continuous ambulatory peritoneal dialysis therapy. Five patients received a single 1,000-mg dose and the other five received a single 2,000-mg dose; all doses were given as 30-min intravenous infusions. Serial plasma, urine, and peritoneal dialysate samples were collected; and the concentrations of cefepime in these fluids were measured over 72 h by using a high-performance liquid chromatographic assay with UV detection. Pharmacokinetic parameters were calculated by noncompartmental methods. The peak concentrations in plasma and the areas under the plasma concentration-versus-time curve for the 2,000-mg dose group were twice as high as those observed for the 1,000-mg dose group. The elimination half-life of cefepime was about 18 h and was independent of the dose. The steady-state volume of distribution was about 22 liters, and values for the 1,000- and 2,000-mg doses were not significantly different. The values for total body clearance and peritoneal dialysis clearance were about 15 and 4 ml/min, respectively. No dose dependency was observed for the clearance estimates. Over the 72-h sampling period, about 26% of the dose was excreted intact into the peritoneal dialysis fluid. For 48 h postdose, mean concentrations of cefepime in dialysate at the end of each dialysis interval exceeded the reported MICs for 90% of the isolates (MIC90s) for bacteria which commonly cause peritonitis resulting from continuous peritoneal dialysis. A parenteral dose of 1,000 or 2,000 mg of cefepime every 48 h would maintain the antibiotic levels in plasma and peritoneal fluid above the MIC90s for the most susceptible bacteria for the treatment of systemic and intraperitoneal infections [corrected].
机译:在接受连续非卧床腹膜透析治疗的10例男性患者中研究了头孢吡肟的药代动力学。五名患者接受了1,000毫克的单剂剂量,其他五名患者接受了2,000毫克的单剂剂量;所有剂量均为30分钟静脉输注。收集血浆,尿液和腹膜透析液样品;并使用高效液相色谱和紫外检测技术在72小时内测量了这些液体中头孢吡肟的浓度。通过非房室方法计算药代动力学参数。 2,000 mg剂量组的血浆峰值浓度和血浆浓度与时间的关系曲线下面积是1,000 mg剂量组的两倍。头孢吡肟的消除半衰期约为18小时,与剂量无关。稳态分布体积约为22升,1,000和2,000 mg剂量的值没有显着差异。全身清除率和腹膜透析清除率分别为约15和4ml / min。对于清除率估计未观察到剂量依赖性。在72小时的采样期间,约有26%的剂量原样排泄到腹膜透析液中。用药后48小时,在每次透析间隔结束时,透析液中头孢吡肟的平均浓度超过了报告的MIC值,其中90%的细菌分离株(MIC90s)通常由连续腹膜透析引起腹膜炎。每48小时肠胃外注射1,000或2,000 mg头孢吡肟,可使最易感染的细菌的血浆和腹膜液中抗生素水平保持在MIC90以上,以治疗全身和腹膜内感染[已纠正]。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号